We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs, Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Recalls Increase Slightly Third Year in a Row

Recalls Increase Slightly Third Year in a Row

January 16, 2015

Drug recalls increased for the third straight year, with companies pulling six percent more products in 2014 than the year before and foreign particles being the top culprit.

The FDA recorded 337 pharmaceutical recalls in 2014, above last year’s total of 315, and up from 291 events in 2012, according to an analysis of agency enforcement reports.

The leading cause for recalls by a wide margin was foreign particles in the drug product, resulting in 55 recalls. Drugmakers reported recalling products containing such things as hair, steel and glass. That figure is well above last year’s total of 19 recalls attributed to foreign particles.

Drug products that failed impurity testing and those with labeling errors tied for second place, with each causing 31 recalls. Subpotent drugs (22 recalls) and products that failed to dissolve properly (20 recalls) accounted for the rest the top events.

One startling trend last year was the spike in the most serious Class I recalls, which at 47 recalls was 45 percent above 2013’s total of 25.

Compounding pharmacies were responsible for almost 8 percent of the overall total, accounting for 28 events in 2014. That figure is slightly below the previous year’s total of 28 recalls. The cause of a majority of compounding recalls was a lack of sterility assurance of the compounded products. The agency has clamped down on compounders since a 2012 deadly outbreak of fungal meningitis attributed to poor quality drugs.

Biologic recalls continued at a low rate in 2014, with only four drugs or vaccines being pulled. Similarly, in 2013, only five biologic products were recalled.

The three-year increase comes as the FDA is changing how it plans to approve some recalls. The agency said recently it will decentralize approval authority for Class I recalls, eliminating the requirement that an associate commissioner approve the Class I recalls and giving that responsibility to CDER.

Help your company avoid these leading causes of recalls, and overcome any you get hit with. Purchase When Things Go Wrong today!

Drugs Commercial Operations Quality

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Cotras Gets FDA Approval of Virtual Reality Rehab Device

  • FDA Approves Novartis Treatment Combination for Pediatric Glioma

  • FDA Deems Cardiosave Intra-Aortic Balloon Recall Class I

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing